The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Key unmet needs in PTCL & the need for more research in this space
In this video, Tetiana Skrypets, MD, PhD, Istituto Tumori “Giovanni Paolo II” Bari, Bari, Italy, highlights key unmet needs in peripheral T-cell lymphoma (PTCL), emphasizing the rarity and heterogeneity of this disease. Dr Skrypets discusses the need for more effective first- and second-line therapies, as well as the potential for PET-guided approaches to identify high-risk patients and guide treatment strategies. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the first unmet need of course is therapeutic approaches because as you said, for heterogeneity and for rarity, the backbone for the therapy approach is based on the diffuse large B-cell lymphoma, maybe it was the first mistake to extrapolate these types of kind of treatment to T-cell lymphomas. However, the first unmet need is first-line approaches. Then of course we still have a lot of debates on the consolidation therapy with autologous stem cell transplant in the first-line and of course the biggest problem is these types of lymphomas, they are so aggressive and unfortunately the second-line therapies, the third-line therapies, they still didn’t give us quite high response rates and these patients, they progressed, progressed, progressed and even if today we have quite a lot of studies with quite a lot of new agents, but however previously we tried to combine different targeted approaches with standard chemotherapeutic approaches also to intensify the first-line therapy to avoid the possibility of disease progression in the future or refractoriness of disease...
So the first unmet need of course is therapeutic approaches because as you said, for heterogeneity and for rarity, the backbone for the therapy approach is based on the diffuse large B-cell lymphoma, maybe it was the first mistake to extrapolate these types of kind of treatment to T-cell lymphomas. However, the first unmet need is first-line approaches. Then of course we still have a lot of debates on the consolidation therapy with autologous stem cell transplant in the first-line and of course the biggest problem is these types of lymphomas, they are so aggressive and unfortunately the second-line therapies, the third-line therapies, they still didn’t give us quite high response rates and these patients, they progressed, progressed, progressed and even if today we have quite a lot of studies with quite a lot of new agents, but however previously we tried to combine different targeted approaches with standard chemotherapeutic approaches also to intensify the first-line therapy to avoid the possibility of disease progression in the future or refractoriness of disease. But unfortunately quite a lot of studies were failed. Of course we have to create based also on our data, I think it’s another one unmet need, some kind of PET-guided approaches to follow treatment strategies, to have a possibility to understand which patients will progress, which patient maybe doesn’t have such high risk for the possible disease progression. Because unfortunately in the routine clinical practice with quite a lot of patients with peripheral T-cell lymphomas, they will never achieve a response rate and they will not be able to arrive until the sixth cycle of the first-line therapy. So maybe also future studies on interim PET are needed to understand how to catch these high-risk group patients and maybe to proceed directly with transplantation or maybe to add another treatment strategy. So there are quite a lot of hypotheses about peripheral T-cell lymphomas. However, there is still quite a lot of work to do.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
